The Danish Competition Council has approved Orifarm’s acquisition of certain assets from Takeda subject to commitments

The Danish Competition Council has approved Orifarm Generics Holding’s (hereinafter “Orifarm”) acquisition of certain assets, including a product portfolio consisting of prescription pharmaceuticals, over-the-counter pharmaceuticals, vitamin and dietary supplements and herbal medicines and two manufacturing sites from Takeda Pharmaceuticals International AG (hereinafter “Takeda”). Orifarm has committed to divest a series of products as a condition of the approval.